Humoral and cellular immune response to AZD1222 /Covishield and BV152/Covaxin COVID-19 vaccines among adults in India

Humoral and cellular immune response to AZD1222 /Covishield and BV152/Covaxin COVID-19 vaccines among adults in India

Several COVID-19 vaccines were developed using different approaches to prevent both symptomatic COVID-19 cases and fatalities. The adults were vaccinated with two doses of AZD1222/Covishield (n = 77) [manufactured by Serum Institute of India Pvt Ltd] vaccine and BV152/Covaxin (n = 99) [manufactured...

Full description

Saved in:
Bibliographic Details
Main Authors: Anuradha S. Tripathy, Dharmendra Singh, Diptee Trimbake, Sukeshani Salwe, Srikanth Tripathy, Arjun Kakrani, Priyanka Jali, Hanmant Chavan, Pragya Yadav, Rima Sahay, Prakash Sarje, Prasad Babar, Anita Shete, Ashok Nandapurkar, Milind Kulkarni
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
AZD1222/Covishield
BV152/Covaxin
SARS CoV-2 specific IgG and “Neutralizing antibodies”
“T cell response”
“B-lymphocytes memory”
“T-lymphocytes memory”
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2410579
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2024.2410579

Similar Items